Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phentolamine - Opus Genetics

Next Previous
Search
Drug Profile

Phentolamine - Opus Genetics

Alternative Names: 0.75% phentolamine ophthalmic solution - Ocularis Pharma; 1% phentolamine mesylate - Ocularis Pharma; Nyxol; Phentolamine mesylate ophthalmic solution - Ocularis Pharma; RYZUMVI

Latest Information Update: 10 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ocularis Pharma
  • Developer Opus Genetics
  • Class Antiglaucomas; Erectile dysfunction therapies; Eye disorder therapies; Imidazoles; Peripheral vasodilators; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Mydriasis
  • Phase III Nyctalopia; Presbyopia
  • Phase II Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 31 Mar 2025 Ocuphire Pharma completes enrollment in the phase III LYNX-2 trial in Nyctalopia (Dim light vision disturbances) (Ophthalmic, Solution) in the US (NCT06349759)
  • 10 Mar 2025 Opus Genetics completes enrolment in its phase III VEGA-3 trial for Presbyopia in USA
  • 26 Feb 2025 Phentolamine - Opus Genetics receives Fast Track designation for Nyctalopia [Ophthalmic,Drops] in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top